Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
With Governor Cuomo
"UK variant"- An analysis of 641 COVID-19 cases found "S-negative" (B.1.1.7 inferred) cases had 10 to 100-times higher nasal viral loads than 'regular' COVID-19. Virologically, that is a massive difference. It could easily explain higher transmissibility. "...the viral load data have me convinced enough that, overall, this mutant is significantly different."-Shane Crotty- Vaccine scientist. Immune system scientist. Professor, La Jolla Institute for Immunology (LJI), a non-profit scientific research institute.
UK strain
JP approval likely comes first week of 2021
If we see a form 4 for 1m shares bot tomorrow morning
NFL commercial was a good sign to me
I am pretty sure OPK is profitable without the current PCR testing revenue stream. Today was just tutes pray on retail.
Frost should have saved up plenty of dry powders for the past half-year. He has been itching to get more OPK shares since Sian attach. We had 3 huge $4 limit order buys today. Frost knows the demand will be huge for BRL and Rayaldee (just renal indications) for the Covid19 long term conditions even Covid 19 is completely gone by today. $opk will be sitting at $5 when we are approaching February.
Frost could have loaded millions of shares today.
Frost in action!
It would get real interesting if Frost buys another 100k today.
Rapid COVID-19 Breath Test a Game-Changer
“Breath testing is noninvasive, non-intrusive, and can be performed repeatedly as needed,” Dr. Dweik notes. “It does not have a dose limitation like x-rays, an amount limitation like blood or saliva tests, or a timing limitation like PCR [nasal swab], blood and urine tests.”
Cleveland Clinic researchers, led by Dr. Dweik, will work with the BreathTech team to further develop the company’s BreathTest-1000™ mass spectrometer, which is based on the company’s core mass spectrometry technology currently used for explosives trace detection. It will be developed to detect metabolites associated with respiratory disease, including COVID-19, and potentially screen patients within as little as 60 seconds.
The partnership brings together the breath analysis expertise and clinical resources of the Cleveland Clinic team with the scalable technology and deployment experience of the BreathTech team. The joint team plans to open a clinical trial with the technology in the coming months, starting with a Phase 1 open study to verify detection sensitivity in hospitalized patients with COVID-19.
“Creating a COVID-19 breath test addresses an urgent unmet clinical need today while also setting us up for a better response to the next global pathogen threat,” adds Dr. Dweik.
https://my.clevelandclinic.org/giving/about/publications/december-3-2020
Right now Frost controls 225m OPK shares!!!
Wondering how much Premium the buyer is going to pay! https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160358467
Frost might be buying again today. He should be very bullish for 2021.
Frost was signaling with his purchase. Soma is big
The fundamental for opk has never been better.
75-year-old Israeli man dies 2 hours after getting Covid-19 vaccine
75-year-old from Beit Shean dies after getting Pfizer vaccine
https://www.israelnationalnews.com/News/News.aspx/293865
Shorts are using the end of year tax loss sale to push down. It will reverse in a week.
DEC 23, 2020
MYXR Inc. Launches Equity Offering on Netcapital
PRESS RELEASE
https://netcapital.com/news#myxr-inc--launches-equity-offering-on-netcapital
Company Looks to Disrupt the Way Organizations Engage Users Through Engagement Software and Augmented Reality Syndication
SAN FRANCISCO (December 23, 2020) – MYXR Inc., an engagement software and augmented reality syndication company that provides a suite of products and solutions across multiple vertical industries, announced a private market equity offering on the Netcapital funding portal.
The company is offering $250,000 to investors as it is about to release its two main software platforms, Engage 2.0 and Experience Platform 3.0, scheduled for roll out in 2021. NetCapital was chosen for this raise because of its commitment to compliance, ease of use by investors, and availability of liquidity to their investors.
MYXR, based in San Francisco, works internationally with companies, entertainment groups, governments, non-profits, schools, professional sports groups and leading brands to enhance the experience and engagement of their clients or constituents through its software and augmented reality (AR) products.
“We're passionate to inspire, empower, and entertain with our platforms - for our users and partners around the world,” said Hans Koch, Chairman, and CEO of MYXR.”With the new digital landscape today, we are seeing demand globally for our platforms, and after years of work, we are excited to bring them to market in 2021.”
MYXR’s platform is proving to be particularly useful during the COVID-19 pandemic. Using gamification technology, Engage 2.0c is designed to reward users for actions taken to benefit others. So, for example, the platform can be used to reward checking on the health conditions of others, donate food or blood to those in need. Users will earn points redeemable with partner brands and local partners.
The company, formed in 2017 and post revenue, was recently rebuilt with a global mindset. MYXR designs its products with the user in mind, seeking their input as the product is refined throughout its development. “Our business thesis is to understand the user first, and then build products for them to deliver ROI to all the stakeholders of the company,” Koch said.
Information on the offering can be found at https://netcapital.com/companies/myxr
https://netcapital.com/news#myxr-inc--launches-equity-offering-on-netcapital
2021 is looking good for OPK. Iam waiting on the PDUFA news
Pink Current Information
Penny Stock Exempt
NCPL at $4.01 while STGC at $18.9
https://vimeo.com/495032819 I cannot imagine Frost paying for a football commercial. More likely Cohen's work! Thank you, Dr. Cohen!
OPK Short Interest
SETTLEMENT DATESHORT INTERESTAVG. DAILY SHARE VOLUMEDAYS TO COVER12/15/2020123,663,8887,756,80315.94263611/30/2020127,120,7744,769,43426.65322
U r right. On nv sos
I see 200m
Authorized Shares
200,000,000
12/23/2020
This was why I said with PDUFA date.
The way it is trading we should expect Somatrogon BLA PDUFA news soon
It should be in Sian's filing.
To piss off Sian. Frost wants to show he still gets this
Button. Sorry
Now NCPL provides a reserve bottom before the offering starts.
Loaded a ton today
Covid19 is not going away for years https://twitter.com/i/events/1340688758950285316
Chamath always has an exist plan in place. Buy with confidence!
Please note that I filed a Form 4 for the sale of 3.8M shares of SPCE. I sold these shares to help manage my liquidity as I fund several new projects starting in 2021. I remain committed and excited for the future of SPCE. Just wanted to be transparent.https://t.co/OsUaVgVwKF
— Chamath Palihapitiya (@chamath) December 17, 2020
I am building a position. Chamath always have an existing plan. Expecting pumping after merge like the other one